Spatial distribution of SARS-CoV-2 seroprevalence in the Administrative Region of Estrutural, Federal District, Brazil
DOI:
https://doi.org/10.5433/1679-0367.2025v46n2p162Keywords:
Spatial distribution, Seroprevalence, SARS-CoV-2, COVID-19Abstract
Introduction: Understanding the seroprevalence of SARS-CoV-2 and its spatial distribution in Estrutural is crucial for properly targeting public health policies in future epidemic situations. Methods: We conducted a spatial analysis study of seroprevalence and associated factors in the SCIA/Estrutural Administrative Region between May 27 and September 19, 2021. We administered questionnaires and performed IgG serological tests for SARS-CoV-2 antibodies on a sample of 1057 participants, analyzing demographic, socioeconomic variables, antibody presence for the virus, and their spatial distribution. A sample of 1054 was considered for spatial analysis. Results: Out of 1057 participants, 201 tested positive for SARS-CoV-2 antibodies. The estimated prevalence was 19.11% (95% CI; 16.85% to 21.59%). In the logistic regression model, having a monthly income of up to one minimum wage showed a negative association (OR = 0.46; 95% CI 0.25 to 0.83). Spatial analysis identified Chácara Santa Luzia as the area with the highest density of SARS-CoV-2 seropositive participants. Discussion: Nearly a quarter of the population had been infected early in the pandemic among the studied population. The spatial analysis identified a clustering of seropositive participants in the most vulnerable area of Estrutural, demonstrating that the spatial distribution is non-homogeneous. This difference may be related to local characteristics of Santa Luzia, such as residential density and residents per household.
Downloads
References
Barros AJD, Victora CG, Menezes AMB, Horta BL, Barros FC, Hartwig FP, Victora GD, Vidaletti LP, Silveira MF, Mesenburg MA, Jacques N, Struchiner CJ, Brust FR, Dall'Agnol MM, Delamare APL, François CHR, Ikeda MLR, Pellegrini DCP, Reuter CP, da Silva SG, Dellagostin OA, Hallal PC.Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil. Rev Saude Publica. 2021;55:78. Doi: https://doi.org/10.11606/S1518-8787.2021055004075.
Capelari MGM, Araújo SMV, Calmon PCDP, Pereira AK, Brasil FL. A trajetória de encerramento do maior lixão da América Latina: entre centralização, descentralização e exclusão. Desenvolv Meio Ambient. 2020;54:146-166. Doi: https://doi.org/10.5380/dma.v54i0.69134.
Companhia de Planejamento do Distrito Federal (Codeplan). Índice de Vulnerabilidade Social do Distrito Federal: resultados. Brasília (DF): Codeplan; 2020. Disponível em: https://agenciabrasilia.df.gov.br/wp-content/uploads/2020/12/2020.12.16-IVS-DF-Resultados.pdf. Acesso em: 25 jun. 2022.
Companhia de Planejamento do Distrito Federal (Codeplan). Pesquisa Distrital por Amostra de Domicílios: SCIA–Estrutural 2018. Brasília (DF): Codeplan; 2020. Disponível em: https://www.codeplan.df.gov.br/wp-content/uploads/2020/06/SCIA-Estrutural.pdf. Acesso em: 10 ago. 2020.
Companhia de Planejamento do Distrito Federal (Codeplan). Pesquisa Distrital por Amostra de Domicílios: SCIA–Estrutural 2021. Brasília (DF): Codeplan; 2022. Disponível em: https://www.codeplan.df.gov.br/wp-content/uploads/2022/05/SCIA.pdf. Acesso em: 1 ago. 2022.
Cruvinel VRN, Costa AM, Silva EN, Fernandes F, Rocha GH, Campos Neto MF, Dias SMF. O fim do maior lixão da América Latina: inclusão socioprodutiva e cuidado com a saúde dos catadores de materiais recicláveis. Santiago: Comissão Econômica para a América Latina e o Caribe; 2020. Disponível em: https://archivo.cepal.org/pdfs/bigpushambiental/Caso79-OFimdoMaiorLixaodaAmericaLatina.pdf. Acesso em: 4 jul. 2024.
Figueiredo GM, Figueiredo Neto JA, Oliveira MHS, Oliveira JG, Silva Júnior GB, Daher EF. Seroprevalence of SARS-CoV-2 in Brazil: a systematic review and meta-analysis. Clinics (Sao Paulo). 2023;78:100233. Doi: https://doi.org/10.1016/j.clinsp.2023.100233.
Fonseca MHG, Silva MFS, Pinto ACMD, Melo ACL, Oliveira FCE, Araújo FMC, Andrade LOM. Persistently positive SARS-CoV-2-specific IgM during 1-year follow-up. J Med Virol. 2022;94(9):4037-4039. Doi: https://doi.org/10.1002/jmv.27822.
Fundação Oswaldo Cruz (Fiocruz). Covid-19: estudo aponta maior risco de contaminação em terminais de ônibus. Rio de Janeiro: Fiocruz; 2021. Disponível em: https://portal.fiocruz.br/noticia/covid-19-estudo-aponta-maior-risco-de-contaminacao-em-terminais-de-onibus. Acesso em: 14 mar. 2022
George CE, Inbaraj LR, Chandrasingh S, de Witte LP. High seroprevalence of COVID-19 infection in a large slum in South India: what does it tell us about managing a pandemic and beyond? Epidemiol Infect. 2021;149:e39. Doi: https://doi.org/10.1017/S0950268821000273.
Lana RM, Freitas LP, Codeço CT, Pacheco AG, Carvalho LMF, Villela DAM, Coelho FC, Cruz OG, Niquini RP, Porto VBG, Gava C, Gomes MFC, Bastos LS. Identificação de grupos prioritários para a vacinação contra COVID-19 no Brasil. Cad Saude Publica. 2021;37(10):e00049821. Doi: https://doi.org/10.1590/0102-311X00049821.
Miranda JM. Infraestrutura e qualidade de vida: o caso da Chácara Santa Luzia–Cidade Estrutural/DF [monografia]. Brasília (DF): Universidade de Brasília; 2016. Disponível em: https://bdm.unb.br/handle/10483/19246. Acesso em: 1 dez. 2020.
Nicol T, Lefeuvre C, Serri O, Pivert A, Joubaud F, Dubée V, Kouatchet A, Ducancelle A, Lunel-Fabiani F, Le Guillou-Guillemette H. Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech). J Clin Virol. 2020;129:104511. Doi: https://doi.org/10.1016/j.jcv.2020.104511.
Nogueira de Brito R, Teixeira AIP, Gontijo CC, Faria RS, Ramalho WM, Sierra Romero GA, Castro M, Pessoa V, Torres LA, Leite LP, Noronha EF, Haddad R, Araújo WN. Seroprevalence of SARS-CoV-2 and Vaccination Coverage among Residents of a Lower-Middle-Class Population in the Federal District, Brazil. Vaccines (Basel). 2023;11(5):916. Doi: https://doi.org/10.3390/vaccines11050916.
Ong DSY, Fragkou PC, Schweitzer VA, Chemaly RF, Moschopoulos CD, Skevaki C, European Society of Clinical Microbiology and Infectious Diseases Study Group for Respiratory Viruses (ESGREV). How to interpret and use COVID-19 serology and immunology tests. Clin Microbiol Infect. 2021;27(7):981-986. Doi: https://doi.org/10.1016/j.cmi.2021.05.001.
Shang Z, Chan SY, Liu WJ, Li P, Huang W. Recent insights into emerging coronavirus: SARS-CoV-2. ACS Infect Dis. 2021;7(6):1369-1388. Doi: https://doi.org/ https://doi.org/10.1021/acsinfecdis.0c00646.
Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol. 2020;10:587269. Doi: https://doi.org/ https://doi.org/10.3389/fcimb.2020.587269.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Rafael da Silva Faria, Raíssa Nogueira de Brito, Ana Izabel Passarella Teixeira, Carolina Carvalho Gontijo, Gustavo Adolfo Sierra Romero, Rodrigo Haddad, Wildo Navegantes de Araújo, Walter Massa Ramalho
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
adopts the CC-BY-NC license for its publications, the copyright being held by the author, in cases of republication we recommend that authors indicate first publication in this journal.
This license allows you to copy and redistribute the material in any medium or format, remix, transform and develop the material, as long as it is not for commercial purposes. And due credit must be given to the creator.
The opinions expressed by the authors of the articles are their sole responsibility.
The magazine reserves the right to make normative, orthographic and grammatical changes to the originals in order to maintain the cultured standard of the language and the credibility of the vehicle. However, it will respect the writing style of the authors. Changes, corrections or suggestions of a conceptual nature will be sent to the authors when necessary.
This Journal is licensed with a license Creative Commons Assignment-NonCommercial 4.0 International.
